{"id":137912,"date":"2022-04-10T01:02:45","date_gmt":"2022-04-10T06:02:45","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2022\/04\/cms-made-the-wrong-decision-on-aduhelm-but-there-might-be-a-silver-lining"},"modified":"2022-04-10T01:02:45","modified_gmt":"2022-04-10T06:02:45","slug":"cms-made-the-wrong-decision-on-aduhelm-but-there-might-be-a-silver-lining","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2022\/04\/cms-made-the-wrong-decision-on-aduhelm-but-there-might-be-a-silver-lining","title":{"rendered":"CMS made the wrong decision on Aduhelm. But there might be a silver lining"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/cms-made-the-wrong-decision-on-aduhelm-but-there-might-be-a-silver-lining3.jpg\"><\/a><\/p>\n<p>CMS officials disagree with the FDA\u2019s reasoning, and are likely worried about the cost of covering a medication for hundreds of thousands of beneficiaries who might seek the treatment if it was broadly covered by Medicare. While CMS\u2019s concern for taxpayers is understandable, it\u2019s the FDA \u2014 not CMS \u2014 that has the statutory authority and deep medical expertise to assess a drug for approval. And Aduhelm passed the FDA\u2019s assessment.<\/p>\n<p>CMS arguably overstepped the bounds of its authority. Its decision is a huge blow to millions of Americans living with Alzheimer\u2019s and their families. They are the losers in CMS\u2019s decision, not only from the severe restriction on access to Aduhelm but also from its chilling effect on the development of other disease-modifying agents for people with Alzheimer\u2019s. If CMS won\u2019t pay for a treatment after the FDA legally approves it, why should a company bother pursuing this pathway?<\/p>\n<p>CMS\u2019s decision will affect the exploration for new treatments for Alzheimer\u2019s for years, just at the time when new drugs appear to be making progress against this terrible disease.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>CMS officials disagree with the FDA\u2019s reasoning, and are likely worried about the cost of covering a medication for hundreds of thousands of beneficiaries who might seek the treatment if it was broadly covered by Medicare. While CMS\u2019s concern for taxpayers is understandable, it\u2019s the FDA \u2014 not CMS \u2014 that has the statutory authority [\u2026]<\/p>\n","protected":false},"author":556,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,47],"tags":[],"class_list":["post-137912","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-neuroscience"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/137912","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/556"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=137912"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/137912\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=137912"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=137912"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=137912"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}